Teresa Frahm
Nurse Practitioner · Superior, NENPI 1477530020
Payments from drug & device makers
Across 140 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$603
- Otsuka America Pharmaceutical, Inc.$445
- Amgen$341
- Novo Nordisk$190
- Johnson & Johnson$111
- Gilead$91
- plus $504 from 12 others
What the payments were for
- Food & beverage$2,284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $603 |
| Otsuka America Pharmaceutical, Inc. | 22 | $445 |
| Amgen | 26 | $341 |
| Novo Nordisk | 12 | $190 |
| Johnson & Johnson | 6 | $111 |
| Gilead | 6 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $90 |
| Alkermes, Inc. | 1 | $83 |
| Astellas Pharma US Inc | 5 | $82 |
| Lundbeck LLC | 3 | $49 |
| Axsome Therapeutics, Inc. | 3 | $47 |
| Abbott | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Pfizer | 2 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Biocryst US Sales Co., LLC | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$2,284 in reported general payments places this provider in the 85th percentile of 924 nurse practitioner providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 62 | $61,544 |
| NuplazidPimavanserin Tartrate | 11 | $61,166 |
| Invega SustennaPaliperidone Palmitate | 20 | $58,510 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $38,565 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 118 | $3,800 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $2,062 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 51 | $2,060 |
| Lurasidone Hcl | 15 | $1,889 |
| Duloxetine Hcl | 139 | $1,404 |
| Carbamazepine ErCarbamazepine | 13 | $1,127 |
| Aripiprazole | 82 | $1,053 |
| Clozapine | 17 | $891 |
| Quetiapine Fumarate | 115 | $888 |
| Sertraline Hcl | 70 | $870 |
| Bupropion XlBupropion Hcl | 50 | $813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $445 | $61,54462 claims |
| Johnson & JohnsonInvega Sustenna | $111 | $58,51020 claims |
| Alkermes, Inc.Lybalvi | $83 | $38,56525 claims |
| Lilly USA, LLCOlanzapine | $12 | $76877 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Superior
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Winifred SchaedelPalmyra$64K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Jodi FuehrerGrand Island$25K
- Amanda GuggenmosOmaha$23K
- Lisa OstendorfLincoln$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.